© 2024 HSP News Service, L.L.C.
In a Chinese single-center phase II study reported in The Lancet Oncology, Pan et al found that sequential CD19- and CD22-directed chimeric antigen receptor (CAR) T-cell therapy was active in pediatric patients with refractory or relapsed B-cell acute lymphocytic leukemia (ALL). Study Details In...
Researchers have found that a text message–based program in combination with routine laboratory testing could safely accelerate patients to treatment with immune checkpoint inhibitors, eliminate the need for in-person assessments with their physicians, and save them about 1.5 hours in total wait...
Early-phase trials demonstrate the potential for TROP-2–directed antibody-drug conjugates to enhance the response to immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC) without actionable genomic alterations, several investigators reported at the International...
In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab. These and other results of...
Researchers have found that nivolumab in combination with a chemotherapy regimen may improve the rate of survival in patients with metastatic urothelial carcinoma, according to new findings simultaneously published by van der Heijden et al in The New England Journal of Medicine and presented at the ...
Compared with neoadjuvant chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival in patients with resectable early-stage non–small cell lung cancer (NSCLC). Results from the phase III CheckMate 77T study were presented at the ...
On October 16, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as postsurgical adjuvant treatment, for resectable (tumors ≥ 4 cm or node-positive)...
Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...
The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...
On October 13, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) for the adjuvant treatment of completely resected stage IIB or IIC melanoma in patients aged 12 years and older. CheckMate 76K Efficacy was evaluated in CheckMate 76K (ClinicalTrials.gov identifier NCT04099251),...
Clear cell renal cell carcinoma is the most common type of kidney cancer, comprising 80% of all malignant tumors found within the kidney. Although some clear cell renal cell carcinoma tumors are sensitive to immune checkpoint inhibitors, currently, there are no measures to predict whether a tumor...
In a Chinese phase 1b/II trial (COMPASSION-03) reported in The Lancet Oncology, Gao et al found that the anti–PD-1/CTLA-4 bispecific antibody cadonilimab showed activity in previously treated patients with a range of advanced solid tumors, including advanced cervical cancer, esophageal squamous...
Justin F. Gainor, MD, Director of the Center for Thoracic Cancers Program at Massachusetts General Hospital, Boston, was invited to discuss IMpower151 and ILLUMINATE at the 2023 World Conference on Lung Cancer. IMpower151 vs IMpower150 Dr. Gainor examined why IMpower151 was negative for both...
In advanced non–small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR), the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study ...
The Alliance Data and Safety Monitoring Board has determined that adjuvant pembrolizumab may improve disease-free survival in patients with localized muscle-invasive urothelial carcinoma and locally advanced urothelial carcinoma, according to the Alliance for Clinical Trials in Oncology. ...
Shirish M. Gadgeel, MD, of the Henry Ford Cancer Institute, discusses a 5-year follow-up study of patients with metastatic non–small cell lung cancer (NSCLC) who were treated with pembrolizumab plus chemotherapy. According to Dr. Gadgeel, the findings continue to support the use of pembrolizumab plus chemotherapy as a standard-of-care first-line treatment, including in tumors with a PD-L1 tumor proportion scores of less than 1%.
Neoadjuvant immunotherapy may be effective prior to surgery in multiple types of cancers, according to a recent study published by Topalian et al in Cancer Cell. Background Neoadjuvant immune checkpoint blockades have been a rapidly growing area of research and are currently being tested across...
As reported in the Journal of Clinical Oncology, Markus Moehler, MD, and colleagues found that in the phase III CheckMate 649 trial, the addition of nivolumab to chemotherapy was associated with generally better patient-reported health-related quality of life outcomes in patients with advanced...
In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...
The anti–PD-L1 monoclonal antibody durvalumab in combination with other immuno-oncology agents may outperform treatment with durvalumab alone in the neoadjuvant setting for patients with early-stage non–small cell lung cancer (NSCLC), according to a recent study published by Cascone et al in Cancer ...
In an interim analysis of a small phase I study reported in The New England Journal of Medicine, Chiesa et al found that base-edited CAR7 T cells were active in pediatric patients with relapsed T-cell acute lymphoblastic leukemia (ALL). As stated by the investigators: “Cytidine deamination that is...
Researchers have discovered that therapy with first-line nivolumab in combination with ipilimumab may improve the 6-year survival and quality of life of patients with metastatic non–small cell lung cancer (NSCLC) compared with standard chemotherapy, according to findings presented by Peters et al...
Barbara Burtness, MD, the Anthony N. Brady Professor of Medicine and Chief Translational Research Officer at Yale Cancer Center, New Haven, featured the CONTINUUM study at the head and neck cancer session on Highlights of the Day during the 2023 ASCO Annual Meeting. She noted the study’s premise...
The addition of the PD-1 inhibitor sintilimab to standard induction chemotherapy and chemoradiotherapy resulted in a significant improvement in 3-year event-free survival, a manageable safety profile, and comparable quality of life in high-risk, locally advanced nasopharyngeal carcinoma vs standard ...
The invited discussant of the VERSATILE-002 and CUE-101-01 trials, Erminia Massarelli, MD, PhD, MS, said both are examples of a growing interest in evaluating immunotherapeutic strategies and treatment sequences in early-stage head and neck squamous cell cancer as well as in metastatic disease. Dr. ...
Immunotherapeutics that target human papillomavirus (HPV) genotype 16 appear to boost the activity of pembrolizumab in advanced head and neck squamous cell carcinoma. Two examples were presented in posters at the 2023 ASCO Annual Meeting.1,2 The phase II VERSATILE-002 trial evaluated PDS0101,...
ASCO EXPERT Peter Paul Yu, MD, FACP, FASCO, commented on the implications of the study presented by Zhao et al. Dr. Yu is Physician-in-Chief at the Hartford HealthCare Cancer Institute. “Tumor microbiome studies are at the cutting edge of precision medicine metabolomics,” Dr. Yu stated....
In patients with advanced hepatocellular carcinoma (HCC), gut microbiome characteristics differed between those who had durable responses to immunotherapy and those who did not, according to a retrospective study presented at the 2023 ASCO Breakthrough meeting.1 The presence of Clostridium...
In a systematic review and meta-analysis reported in JAMA Oncology, Xie et al explored outcomes associated with immune checkpoint inhibition among patients with advanced hepatocellular carcinoma with Child-Pugh B vs Child-Pugh A liver function. Study Details The analysis included 22 studies...
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
In the phase III ATALANTE/ENGOT-ov29 trial reported in the Journal of Clinical Oncology, Kurtz et al found that the addition of atezolizumab to bevacizumab and platinum-based doublets did not significantly improve progression-free survival among patients with platinum-sensitive ovarian cancer....
Researchers have identified new strategies to help physicians predict which patients with advanced colorectal cancer may benefit from immunotherapy, according to a recent study published by Saberzadeh-Ardestani et al in Clinical Cancer Research. The findings demonstrate the potential of using...
In an analysis reported in a letter to the editor in The New England Journal of Medicine, Palmer et al identified evidence that polatuzumab vedotin-piiq–containing regimens were preferentially effective among patients with diffuse large B-cell lymphoma (DLBCL) with activated B cell (ABC) vs...
In a Spanish phase II study (Atezo-Brain; GECP17/05) reported in the Journal of Clinical Oncology, Ernest Nadal, MD, PhD, and colleagues investigated the activity of the combination of atezolizumab with chemotherapy in patients with advanced nonsquamous non–small cell lung cancer (NSCLC) with...
In a Swiss phase II study (SAKK 06/17) reported in the Journal of Clinical Oncology, Richard Cathomas, MD, and colleagues found that the addition of perioperative durvalumab to neoadjuvant chemotherapy resulted in improved event-free and overall survival in patients with muscle-invasive urothelial...
In a retrospective cohort study reported in JAMA Network Open, Goodman et al found that patients receiving adjuvant PD-1 inhibitor therapy for high-risk resected melanoma often had chronic immune-related adverse events, with some persisting over long-term follow-up. Study Details The study included ...
Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study published by VanderWalde et al in Nature Medicine. These findings demonstrated the combination ...
Xin Gao, MD, Assistant Professor, Harvard Medical School, Genitourinary Cancers Program, Mass General Cancer Center, commented on the results from TROPHY-U-01 cohort 2. “These data add to the overall data on the efficacy of sacituzumab govitecan in patients with metastatic urothelial cancer. This...
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
As reported in The New England Journal of Medicine by Heather Wakelee, MD, and colleagues, an interim analysis of the phase III KEYNOTE-671 trial showed that the addition of neoadjuvant pembrolizumab to cisplatin-based chemotherapy followed by adjuvant pembrolizumab improved pathologic response and ...
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Researchers have identified a novel parameter of T cells that may help oncologists anticipate which patients are most likely to develop immunotherapy toxicity. The findings, published by Ostmeyer in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of ...
Penile squamous cell carcinoma is a rare type of penile cancer with limited treatment options. An international study has found that the use of immune checkpoint inhibitors may offer clinical benefits for some patients with advanced penile squamous cell carcinoma. These findings were published by...
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
Researchers may have uncovered the immune adverse events and the specific type of CD8 T cells that characterize inflammatory arthritis induced by immune checkpoint inhibitors, according to a recent study published by Wang et al in Science Immunology. Immune checkpoint inhibitors used to treat...
Matthew J. Frank, MD, PhD, of Stanford University School of Medicine, discusses new findings showing that CD22 chimeric antigen receptor (CAR) T-cell therapy is an effective and safe salvage therapy for patients with CAR19-refractory large B-cell lymphoma. A multicenter phase II clinical trial is planned for 2023 (Abstract S230).
In the phase III CARTITUDE-4 trial reported in The New England Journal of Medicine, San-Miguel et al found that receipt of ciltacabtagene autoleucel following bridging therapy significantly improved progression-free survival vs standard care in patients with lenalidomide-refractory multiple...
In a Chinese phase III study reported in JAMA Oncology, Li et al found that niraparib maintenance therapy given with an individualized starting dose improved progression-free survival vs placebo in newly diagnosed patients with advanced ovarian cancer. Study Details In the double-blind multicenter...
In the phase II I-SABR trial reported in The Lancet, Chang et al found that the addition of nivolumab to stereotactic ablative radiotherapy (SABR) improved event-free survival in patients with previously untreated stage I or II or isolated parenchymal recurrent node-negative non–small cell lung...